Trial Profile

A Multicenter, Single-arm, Open-label, Dose-escalation and Dose-expansion Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WTX 212 (Primary)
Indications Cervical cancer; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Lymphoma; Mycosis fungoides; Oesophageal cancer; Sezary syndrome; Solid tumours
Focus Adverse reactions; First in man
Acronyms Reboot-101
Sponsors Westlake Therapeutics

24 Jul 2024 Planned End Date changed from 31 Jul 2024 to 31 Jul 2026.
24 Jul 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
04 Jun 2024 Results ( By Feb 5th, 2024, n=7)presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com